Email: cspc@cspc.cn
News
News Center
Feb. 07
2024
VOLUNTARY ANNOUNCEMENT-INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (明復樂®) (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS M
Jan. 19
VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
CSPC Listed in Top 100 Enterprises in the Beijing-Tianjin-Hebei Region
CSPC Receives MSCI ESG A Rating for Three Consecutive Years
CSPC Attends 2023 Conference on the Development of China's Pharmaceutical Industry
CSPC Reclaims Top Ten Spot among Top 100 Enterprises in Pharmaceutical Industry!
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
